A comprehensive report of long-term stability data for a range ATMPs : A need to develop guidelines for safe and harmonized stability studies
Copyright © 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved..
BACKGROUND AIMS: Advanced therapy medicinal products (ATMPs) are novel drugs based on genes, cells or tissues developed to treat many different diseases. Stability studies of each new ATMP need to be performed to define its shelf life and guarantee efficacy and safety upon infusion, and these are presently based on guidelines originally drafted for standard pharmaceutical drugs, which have properties and are stored in conditions quite different from cell products. The aim of this report is to provide evidence-based information for stability studies on ATMPs that will facilitate the interlaboratory harmonization of practices in this area.
METHODS: We have collected and analyzed the results of stability studies on 19 different cell-based experimental ATMPs, produced by five authorized cell factories forming the Lombardy "Plagencell network" for use in 36 approved phase I/II clinical trials; most were cryopreserved and stored in liquid nitrogen vapors for 1 to 13 years.
RESULTS: The cell attributes collected in stability studies included cell viability, immunophenotype and potency assays, in particular immunosuppression, cytotoxicity, cytokine release and proliferation/differentiation capacity. Microbiological attributes including sterility, endotoxin levels and mycoplasma contamination were also analyzed. All drug products (DPs), cryopreserved in various excipients containing 10% DMSO and in different primary containers, were very stable long term at <-150°C and did not show any tendency for diminished viability or efficacy for up to 13.5 years.
CONCLUSIONS: Our data indicate that new guidelines for stability studies, specific for ATMPs and based on risk analyses, should be drafted to harmonize practices, significantly reduce the costs of stability studies without diminishing safety. Some specific suggestions are presented in the discussion.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Cytotherapy - 24(2022), 5 vom: 31. Mai, Seite 544-556 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Capelli, Chiara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Advanced therapy medicinal products |
|---|
| Anmerkungen: |
Date Completed 26.04.2022 Date Revised 20.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jcyt.2021.12.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337092265 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337092265 | ||
| 003 | DE-627 | ||
| 005 | 20231225233626.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcyt.2021.12.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1123.xml |
| 035 | |a (DE-627)NLM337092265 | ||
| 035 | |a (NLM)35177338 | ||
| 035 | |a (PII)S1465-3249(22)00007-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Capelli, Chiara |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A comprehensive report of long-term stability data for a range ATMPs |b A need to develop guidelines for safe and harmonized stability studies |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.04.2022 | ||
| 500 | |a Date Revised 20.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND AIMS: Advanced therapy medicinal products (ATMPs) are novel drugs based on genes, cells or tissues developed to treat many different diseases. Stability studies of each new ATMP need to be performed to define its shelf life and guarantee efficacy and safety upon infusion, and these are presently based on guidelines originally drafted for standard pharmaceutical drugs, which have properties and are stored in conditions quite different from cell products. The aim of this report is to provide evidence-based information for stability studies on ATMPs that will facilitate the interlaboratory harmonization of practices in this area | ||
| 520 | |a METHODS: We have collected and analyzed the results of stability studies on 19 different cell-based experimental ATMPs, produced by five authorized cell factories forming the Lombardy "Plagencell network" for use in 36 approved phase I/II clinical trials; most were cryopreserved and stored in liquid nitrogen vapors for 1 to 13 years | ||
| 520 | |a RESULTS: The cell attributes collected in stability studies included cell viability, immunophenotype and potency assays, in particular immunosuppression, cytotoxicity, cytokine release and proliferation/differentiation capacity. Microbiological attributes including sterility, endotoxin levels and mycoplasma contamination were also analyzed. All drug products (DPs), cryopreserved in various excipients containing 10% DMSO and in different primary containers, were very stable long term at <-150°C and did not show any tendency for diminished viability or efficacy for up to 13.5 years | ||
| 520 | |a CONCLUSIONS: Our data indicate that new guidelines for stability studies, specific for ATMPs and based on risk analyses, should be drafted to harmonize practices, significantly reduce the costs of stability studies without diminishing safety. Some specific suggestions are presented in the discussion | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Good Manufacturing Practices | |
| 650 | 4 | |a advanced therapy medicinal products | |
| 650 | 4 | |a potency assays | |
| 650 | 4 | |a quality controls | |
| 650 | 4 | |a shelf life | |
| 650 | 4 | |a stability study | |
| 700 | 1 | |a Frigerio, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Lisini, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Nava, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Gaipa, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Belotti, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Cabiati, Benedetta |e verfasserin |4 aut | |
| 700 | 1 | |a Budelli, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Lazzari, Lorenza |e verfasserin |4 aut | |
| 700 | 1 | |a Bagnarino, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Tanzi, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Comoli, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Perico, Norberto |e verfasserin |4 aut | |
| 700 | 1 | |a Introna, Martino |e verfasserin |4 aut | |
| 700 | 1 | |a Golay, Josée |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cytotherapy |d 1999 |g 24(2022), 5 vom: 31. Mai, Seite 544-556 |w (DE-627)NLM118333852 |x 1477-2566 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2022 |g number:5 |g day:31 |g month:05 |g pages:544-556 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcyt.2021.12.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2022 |e 5 |b 31 |c 05 |h 544-556 | ||